Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) was submitted on November 2, 2020, for the month of November 2020. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a corporate governance notification regarding share capital.
| Metric | Value as of Oct 31, 2020 |
|---|---|
| Issued Share Capital | 5,385,130,582 Ordinary Shares (25 pence each) |
| Treasury Shares | 367,705,950 Ordinary Shares |
| Total Voting Rights | 5,017,424,632 |
Material Changes
The filing does not contain comparative data against prior periods or disclose material changes to financial performance. It solely establishes the denominator for shareholder notification calculations under FCA rules.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. Its scope is limited to the statutory disclosure of voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (5,017,424,632) for compliance with FCA notification thresholds.
- Confirm the number of shares held in Treasury (367,705,950) to calculate the net issued share count accurately.
- Note that this filing does not reflect operational or financial results; refer to Form 20-F or quarterly reports for financial metrics.